Table 1.

Baseline characteristics in all cohorts

Discovery cohortValidation cohortChemotherapy
Number of patients193919
Gender
 Male12 (63.2%)25 (64.1%)11 (57.9%)
 Female7 (36.8%)14 (35.9%)8 (42.1%)
Age, years
 Median (range)57 (20–76)51 (19–73)57 (30–77)
Breslow thickness, mm
 Median (range)3.3 (0.8–13.0)2.1 (0.7–12.0)2.4 (0.4–10.0)
M stage at inclusion
 M1a5 (26.3%)8 (20.5%)a2 (10.5%)
 M1b4 (21.1%)10 (25.6%)3 (15.8%)
 M1c10 (52.6%)21 (53.9%)14 (73.7%)
LDH at inclusion
 Normal13 (68.4%)24 (60.5%)11 (57.9%)
 Elevated6 (31.6%)15 (39.5%)8 (42.1%)
Time to M stage, months
 Mean (range)31.0 (1.1–74.7)39.5 (0.0–137.0)48.6 (7.4–179.9)
Overall survival, months
 Mean (range)22.4 (2.9–130.0)12.5 (1.1–63.9)6.6 (1.2–27.4)
  • aIncludes one irresectable stage III melanoma patient.